ANNAPOLIS, Md., Feb. 1, 2016 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA) Global Board of Directors elected Mr. David Ian Bell as the new Chairman, effective January 2016. Mr. Bell will serve as Chairman for a term of three years.
Mr. Bell, Vice President, Grifols S.A., brings decades of experience in the plasma industry. In his role at Grifols, Mr. Bell has been a key contributor to Grifols ability to manufacture lifesaving therapies that benefit patients with rare diseases.
"I have known David more than 15 years and am looking forward to working with him. His energy and commitment to the industry will be invaluable," stated Jan M. Bult, President and CEO of PPTA.
Mr. Bell succeeds Dr. Paolo Marcucci, President and CEO of Kedrion who held this position from 2013-2015.
"I thank Paolo Marcucci for his contributions as Chair and, as his successor, I will do my utmost to demonstrate our commitment to serving the many patients who rely on the therapies we produce," said Mr. Bell.
About the Plasma Protein Therapeutics Association
The Plasma Protein Therapeutics Association (PPTA), a global industry trade association, represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by millions of people worldwide to treat a variety of diseases and serious medical conditions. PPTA also administers standards and programs that help ensure the quality and safety of plasma protein therapies, donors and patients.
SOURCE Plasma Protein Therapeutics Association (PPTA)